This study concludes that malignant blood disorders represent a leading cause of death, health-care service use, and costs, not only to European health-care systems, but to society overall. It is one of two analyses in The Lancet Haematology, which aimed to quantify the total economic effect of both malignant and non-malignant blood disorders in the 28 members of the European Union, Iceland, Norway, and Switzerland.